Serious adverse events with a greater than 2 % frequency with tecemotide were pneumonia ( 30 [ 3 % ] in the tecemotide group vs 14 [ 3 % ] in the placebo group ) , dyspnoea ( 29 [ 3 % ] vs 13 [ 3 % ] ) , and metastases to central nervous system ( 32 [ 3 % ] vs 9 [ 2 % ] ) .